Figure 2From: Clinical trials with anti-angiogenic agents in hematological malignanciesModes of action of IMiDs. IL-6, interleukin-6; IMiDs, immunomodulatory drugs; NK cells, Natural killer cells; Th1 cells, T helper 1 cells; TNFα, tumor necrosis factor alpha; Treg, regulatory T cells; VEGF, vascular endothelial growth factor.Back to article page